To date, there is strong evidence that CD8+ T cells confer a better prognosis in melanoma patients and that their expansion occurs after anti-CTLA-4 and anti-PD-1 monotherapy as well as anti-PD-1 plus anti-CTLA-4 combination treatment. The gene discussed is CTLA4; the disease is melanoma.